| 1 |
NCT03206099 |
Recruiting |
NIAID Centralized Sequencing Protocol |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Characterize discrete genetic contributions to immune disease including:-Established genetic disorders of the immune system-Novel genetic defects associated with immune disease-Novel clinical phenotypes associated with established ge...
|
10000 |
All |
up to 99 Years (Child, Adult, Senior) |
NCT03206099 |
170122
17-I-0122 |
|
July 31, 2017 |
December 31, 2030 |
December 31, 2032 |
July 2, 2017 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 2 |
NCT02332733 |
Recruiting |
Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand |
|
- Biological: TV003
- Biological: Placebo for TV003
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Occurrence of solicited local and general adverse events (AEs) within the 21-day (Days 0-20) follow-up period after each vaccine dose
- Occurrence of unsolicited AEs within the 21-day (Days 0-20) follow-up period after each vaccine dose
- Occurrence of serious adverse events (SAEs) throughout the entire study period
- (and 6 more...)
|
266 |
All |
12 Months to 50 Years (Child, Adult) |
NCT02332733 |
WRAIR 2041 |
|
November 2014 |
August 2018 |
|
January 7, 2015 |
December 18, 2017 |
|
- Phramongkutklao Hospital
Bangkok, Thailand
|
| 3 |
NCT00789009 |
Recruiting |
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection |
- HIV Infections
- AIDS
- Opportunistic Infections
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
600 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT00789009 |
090030
09-I-0030 |
|
December 1, 2008 |
|
|
November 11, 2008 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 4 |
NCT00344188 |
Recruiting |
Diagnosis and Treatment of Leishmanial Infections |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
100 |
All |
2 Years to 80 Years (Child, Adult, Senior) |
NCT00344188 |
010238
01-I-0238 |
|
August 22, 2001 |
|
|
June 26, 2006 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 5 |
NCT01212003 |
Recruiting |
Training Protocol on the Natural History of Tuberculosis |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Develop on-site NIH Clinical Center (CC)/NIAID experience in the standard of care of tuberculosis patients with drug sensitive and drug resistant disease, as well as latent tuberculosis.
- Characterize in vitro immune responses of patients with tuberculosis to a panel of agonists including but not limited to, strains of Mycobacterium tuberculosis (MTB), MTB antigens, and purified stimuli (e.g. Pam3Cys, LPS, HKLM).
- Characterize lymphoid profiles of patients with drug-sensitive (DS) TB, multi-drug resistant (MDR) TB, and extensively drug-resistant (XDR) TB both during acute, convalescent, and cured disease.
|
150 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01212003 |
100195
10-I-0195 |
|
September 1, 2010 |
|
|
September 30, 2010 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 6 |
NCT00339287 |
Recruiting |
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens |
- Normal Neutrophil Function
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Other
|
- Neutrophil function assays.
|
200 |
All |
21 Years to 65 Years (Adult) |
NCT00339287 |
999901055
01-I-N055 |
|
February 12, 2001 |
|
|
June 21, 2006 |
March 21, 2018 |
|
- NIAID, Rocky Mountain Laboratories
Hamilton, Montana, United States
|
| 7 |
NCT01375530 |
Recruiting |
Screening Volunteers for Clinical Trials |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Other
|
- To screen subjects for their eligibility to participate in clinical trials ofinvestigational products or licensed products being evaluated for research purposes.
|
3000 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01375530 |
110164
11-I-0164 |
|
June 16, 2011 |
|
|
June 17, 2011 |
April 24, 2018 |
|
- Hope Clinic - Emory Vaccine Ctr
Decatur, Georgia, United States - University of Maryland, Baltimore
Baltimore, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 8 |
NCT00001645 |
Recruiting |
Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To evaluate, treat and follow patients with parasitic infections not covered by existing LPD/NIAID protocols
- To screen patients with suspected parasitic infections for enrollment on other LPD/NIAID protocols
|
500 |
All |
1 Year and older (Child, Adult, Senior) |
NCT00001645 |
970096
97-I-0096 |
|
March 24, 1997 |
|
|
November 4, 1999 |
April 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 9 |
NCT00001350 |
Recruiting |
Study of Autoimmune Lymphoproliferative Syndrome (ALPS) |
- Autoimmune Lymphproliferative Syndrome
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Retrospective
|
- The purpose of this family based natural history protocol is to allow for patients, and relatives of patients to be screened for Autoimmune Lymphoproliferative Syndrome (ALPS) and related disorders of apoptosis, RAS associated leukoproliferative...
|
1000 |
All |
Child, Adult, Senior |
NCT00001350 |
930063
93-I-0063 |
|
December 21, 1992 |
|
|
November 4, 1999 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 10 |
NCT03315078 |
Recruiting |
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency |
- X-Linked Combined Immunodeficiency Diseases
|
- Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
- Drug: Palifermin
- Drug: Busulfan
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Level of autologous transduced T-lymphocytes with functional γc
- Incidence of serious side effects due to lentiviral gene transfer
- Distribution of integration sites of the lentiviral vector in reconstituted peripheral blood cells
|
13 |
All |
2 Years to 40 Years (Child, Adult) |
NCT03315078 |
11-I-0007 |
LVXSCID-OC |
April 2012 |
December 2022 |
December 2022 |
October 19, 2017 |
October 19, 2017 |
|
- Laboratory of Host Defenses (LHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Bethesda, Maryland, United States
|
| 11 |
NCT00067054 |
Recruiting |
Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- This protocol does not have an analysis primary outcome measure, but rather will be conducted in accordance with Good Clinical Practices for human research solely for the purpose of obtaining samples for research laboratories. Samples will be id...
|
3000 |
All |
18 Years to 65 Years (Adult) |
NCT00067054 |
030263
03-I-0263 |
|
August 8, 2003 |
|
|
August 11, 2003 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - University of Puerto Rico
Rio Piedras Station, Puerto Rico
|
| 12 |
NCT01547884 |
Recruiting |
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Cross-Sectional
|
- To compare the immune responses to mycobacterial antigens, including PPD and Mycobacterium tuberculosis culture filtrate protein, in individuals who are LTBI+ Fil- versus those who are LTBI+ Fil+.
- To compare immune responses to mycobacterial antigens in LTBI+Fil+ co-infected individuals, before and after treatment for filarialinfection.
|
4000 |
All |
18 Years to 65 Years (Adult) |
NCT01547884 |
999912073
12-I-N073 |
|
February 7, 2012 |
|
|
March 8, 2012 |
October 6, 2017 |
|
- National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi
Bethesda, Maryland, United States
|
| 13 |
NCT03167437 |
Recruiting |
Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease |
|
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability as measured by the rate, frequency, and severity of AEs starting from Day 0 through Week 12.
- To determine the number of participants that achieve a clinicalresponse at Week 12, as defined by a decrease in CDAI from baseline by greater than or equal to 70 points for CD patients.
- To determine the number of participants that achieve clinicalremission at Week 12 as defined by a CDAI score of 150 points or less.
- To determine the number of participants with mucosal healing, asassessed by a decrease in endoscopic scores from baseline to zero (Simple Endoscopic Score Crohn's Disease [SES-CD] for CD) or the number of participants with mucosal response as...
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT03167437 |
170101
17-I-0101 |
|
October 30, 2017 |
March 31, 2020 |
June 30, 2020 |
May 30, 2017 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 14 |
NCT03018275 |
Recruiting |
Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis |
|
- Biological: Roseomonas mucosa
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- A 50% reduction in antecubital-specific SCORing Atopic Dermatitis (SCORAD) with no adverse events related to product use. Frequency of solicited adverse events, unsolicited adverse events, serious adverse events, and death.
- A 30% improvement in the quality of life as measured by the validated Children's Dermatology Life Quality Index (CDLQI)
- A 30% improvement in the quality of life as measured by the validated Family Dermatology Life Quality Index (FDLQI)
|
70 |
All |
3 Years to 99 Years (Child, Adult, Senior) |
NCT03018275 |
170033
17-I-0033 |
|
January 11, 2017 |
May 30, 2019 |
May 30, 2019 |
January 12, 2017 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 15 |
NCT02821832 |
Recruiting |
Using Biomarkers to Predict TB Treatment Duration |
|
- Procedure: blood draw
- Radiation: PET/CT
- Procedure: induced sputum
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Basic Science
|
- The primary endpoint will be a comparison of the rate of treatment success at 18 months between Arms B and C.
- Endpoint relating to imaging include: PET total glycolytic activity volume in regions of interest
- Endpoint relating to imaging include: total volume of hard CT lesions (-100 to 200 Hu)
- (and 3 more...)
|
1000 |
All |
18 Years to 65 Years (Adult) |
NCT02821832 |
999916133
16-I-N133 |
|
June 29, 2016 |
December 30, 2022 |
December 30, 2023 |
July 4, 2016 |
April 6, 2018 |
|
- Xinmi City Center for Disease Control and Prevention
Xinmi, Henan Province, China - Henan Provincial Chest Hospital
Zhengzhou, Henan Province, China - Zhongmu County Station for Disease Control and Prevention
Zhongmu, Henan Province, China
|
| 16 |
NCT02818582 |
Recruiting |
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen |
|
- Drug: GS-5734
- Other: Placebo Comparator
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- To compare the antiviral activity over 28 days following the administration of 5 days of IV GS-5734 versus placebo in male Ebola Virus Disease survivors with evidence of Ebola virus in their semen.
- To compare the effect of 5 days of IV GS-5734 versus placebo on the detection of Ebola RNA in semen of male survivors of Ebola Virus Disease over 24 weeks.
- To evaluate the safety and tolerability of GS-5734 in male Ebola survivors with evidence of Ebola virus in their semen.
- (and 2 more...)
|
120 |
Male |
18 Years and older (Adult, Senior) |
NCT02818582 |
999916137
16-I-N137 |
|
June 28, 2016 |
June 30, 2018 |
January 26, 2019 |
June 29, 2016 |
April 4, 2018 |
|
- National Center for Trainingand Research in Rural Health
Conakry, Guinea - Physician at the service of the Infectious and Tropical Diseases
Conakry, Guinea - JFK Hospital
Monrovia, Liberia - Duport Road PREVAIL Clinic
Paynesville, Liberia
|
| 17 |
NCT02629120 |
Recruiting |
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease |
- X-Linked Chronic Granulomatious Disease
|
- Drug: Campath
- Drug: Busulfan
- Other: allogeneic peripheral blood allograft infusion
- Drug: cyclophosphamide
|
Interventional |
Early Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Reduced incidence of graft failure or rejection (Engraftment as defined by >20% engraftment by oxidase positive neutrophils in at least 95% of participants by Day 100)
- Same or reduced rate of acute Graft versus Host Disease of <20% in subjects who will be receiving a high stem cell dose in combination with post cyclophosphamide.
- Establish stable mixed chimerism.
- Improve rapidity of immune reconstitution.
|
50 |
All |
4 Years to 65 Years (Child, Adult) |
NCT02629120 |
160032
16-I-0032 |
|
December 10, 2015 |
December 31, 2025 |
December 1, 2030 |
December 14, 2015 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 18 |
NCT02496676 |
Recruiting |
Magnesium Supplementation in People With XMEN Syndrome |
- X-linked Immunodeficiency With Magnesium Defect
- Epstein-Barr Virus (EBV) Infection and Neoplasia
|
- Drug: Magnesium L-threonate
- Drug: Placebo
- Drug: Magnesium Sulfate (MgSO)
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To investigate the efficacy of magnesium supplementation in patients with XMEN syndrome by comparing the absolute number ofEBV-infected B cells after 12 weeks of oral magnesium and after 12 weeks of placebo.
- To assess the safety and tolerability of MgSO4 IV infusion and oral magnesium L-threonate
- To evaluate the effects of magnesium supplementation on intracellular free magnesium (Mg2+) concentrations in peripheral blood T cell lymphocytes
- Contingent upon patient participation in Part II, to compare the effects of 2 different supplementation regimens (oral magnesium L-threonate with and without initial infusion of IV MgSO4) on EBV viral load and number (or percent) of EBV-infected...
|
30 |
Male |
6 Years and older (Child, Adult, Senior) |
NCT02496676 |
150161
15-I-0161 |
|
July 9, 2015 |
June 1, 2020 |
December 1, 2020 |
July 14, 2015 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 19 |
NCT02262819 |
Recruiting |
Human Immunity Against Staphylococcus Aureus Skin Infection |
- Staphylococcus Aureus Skin Infection
|
|
Interventional |
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Evaluate the local in vivo skin immune response to bacteria.
- Evaluate the keratinocyte responses to bacterial challenge.
- Determine if abnormalities in specific immune pathways, such as IL-17 and vitamin D metabolism, are present in subjects with recognized susceptibility to S. aureus infections.
- (and 3 more...)
|
300 |
All |
2 Years to 65 Years (Child, Adult) |
NCT02262819 |
140199
14-I-0199 |
|
October 10, 2014 |
January 1, 2025 |
January 1, 2025 |
October 13, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 20 |
NCT02446626 |
Recruiting |
Xenodiagnosis After Antibiotic Treatment for Lyme Disease |
|
- Procedure: Skin biopsy
- Procedure: Blood draw
- Other: Xenodiagnosis
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- This study is powered to detect difference in the positivity rate between symptomatic and asymptomatic individuals.
- The study will continue to assess the safety of xenodiagnosis in humans.
|
240 |
All |
18 Years and older (Adult, Senior) |
NCT02446626 |
150131
15-I-0131 |
|
May 13, 2015 |
December 1, 2020 |
December 1, 2030 |
May 18, 2015 |
March 29, 2018 |
|
- Mansfield Family Practice
Storrs, Connecticut, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Tufts Medical Center
Boston, Massachusetts, United States - New York Medical College
Valhalla, New York, United States
|
| 21 |
NCT02242968 |
Recruiting |
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To develop a pool of subject eligible to participate in clinical trials of investigational or licensed vaccines or antiviral products.
|
1000 |
All |
18 Years to 65 Years (Adult) |
NCT02242968 |
140194
14-I-0194 |
|
September 16, 2014 |
September 30, 2024 |
September 30, 2024 |
September 17, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 22 |
NCT01200953 |
Recruiting |
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases |
- Occupational Accidents
- Incubation Period, Infectious Disese
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
250 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01200953 |
100197
10-I-0197 |
|
September 2, 2010 |
|
|
September 14, 2010 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 23 |
NCT00471302 |
Recruiting |
Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Bamako
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Obtain blood samples from healthy Malian adults in order to establish normal immunologic parameters for this population and to optimize research assays performed at the MRTC.
|
450 |
All |
18 Years to 55 Years (Adult) |
NCT00471302 |
999907141
07-I-N141 |
|
May 7, 2007 |
|
|
May 9, 2007 |
April 20, 2018 |
|
- University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology
Bamako, Mali - Kalifabougou Health Center
Kalifabougou, Mali - Tieneguebougou Health Center
Tieneguebougou, Mali
|
| 24 |
NCT00132327 |
Recruiting |
Analysis of Lyme Disease Lesions |
- Erythema Migrans Lesions
- Erythema Migrans
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00132327 |
050219
05-I-0219 |
|
August 17, 2005 |
|
|
August 19, 2005 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 25 |
NCT00091871 |
Recruiting |
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression |
- Familial Hypereosinophilia
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- To study the natural history of familial hypereosinophilia (FE)
- To determine the immunologic and molecular mechanisms responsible for eosinophilia, eosinophil activation, and pathogenesis in FE
- To identify early clinical or laboratory markers of disease progression in FE
|
50 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT00091871 |
040286
04-I-0286 |
|
September 15, 2004 |
|
|
September 20, 2004 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 26 |
NCT00426517 |
Recruiting |
Donor Stem Cell Transplantation for Congenital Immunodeficiencies |
- Inherited Immune Deficiencies
|
- Drug: Fludarabine
- Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine
- Drug: Sirolimus or equivalent based on response
- (and 2 more...)
|
Interventional |
Early Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective for this study is to evaluate the use of immunosuppressive drugs such as Campath -1H or h-ATG, fludarabine, and sirolimus in conjunction with a novel busulfan-based conditioning regimen with or without the addition of radia...
- To measure the engraftment rate and the engraftment kinetics using such a regimen
- To further elucidate the required dose levels of busulfan as compared to historical controls in conditioning regimens for transplantation in general
- To assess the level and kinetics of immune reconstitution when using these conditioning regimens. To further elucidate the factors involved in the development of graft versus host disease.
|
100 |
All |
2 Years to 40 Years (Child, Adult) |
NCT00426517 |
070075
07-I-0075 |
|
January 19, 2007 |
December 1, 2020 |
December 1, 2023 |
January 24, 2007 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 27 |
NCT00028080 |
Recruiting |
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
400 |
All |
Child, Adult, Senior |
NCT00028080 |
020055
02-I-0055 |
|
November 21, 2001 |
|
|
December 12, 2001 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 28 |
NCT00001406 |
Recruiting |
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia |
- Asthma
- Eosinophilia
- Helminthiasis
- (and 2 more...)
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
800 |
All |
1 Year to 100 Years (Child, Adult, Senior) |
NCT00001406 |
940079
94-I-0079 |
|
February 11, 1994 |
|
|
November 4, 1999 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 29 |
NCT00001539 |
Recruiting |
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Long term outcome
- Immunological markers
- Biomarkers
|
600 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00001539 |
960052
96-I-0052 |
|
March 25, 1996 |
|
|
November 4, 1999 |
April 20, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 30 |
NCT02257892 |
Recruiting |
Novel Genetic Disorders of the Immune System |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Diagnosis of an underlying genetic defect for patient's immune disorder
|
500 |
All |
up to 99 Years (Child, Adult, Senior) |
NCT02257892 |
140206
14-I-0206 |
|
October 4, 2014 |
August 30, 2024 |
August 30, 2025 |
October 7, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 31 |
NCT02190266 |
Recruiting |
Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Arizona
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- 1)Identify known and novel immune defects
- 2)Characterize the demographics of patients afflicted with this disease
- 3)Characterize the phylogeny of infecting coccidioidomycoses
|
60 |
All |
2 Years and older (Child, Adult, Senior) |
NCT02190266 |
140146
14-I-0146 |
|
July 12, 2014 |
July 31, 2020 |
July 31, 2020 |
July 15, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 32 |
NCT02199496 |
Recruiting |
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency |
- CVID
- Enteropathy
- Chronic Diarrhea
- (and 2 more...)
|
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint of the study is whether treatment with ustekinumab is safe and tolerated in CVID enteropathy patients and does not cause a significant increase in infection or result in any serious adverse events (SAEs) that are determined...
- The secondary endpoint of the study is whether patients respond to the treatment with ustekinumab. Response will be defined as <1% decrease in weight or a decrease in the number of stools at the Week 8, Week 16, Week 24, Week 32 and Week 40 v...
|
10 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02199496 |
140153
14-I-0153 |
|
July 23, 2014 |
December 31, 2018 |
December 31, 2019 |
July 24, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 33 |
NCT02116764 |
Recruiting |
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 |
- Chronic Granulomatous Disease
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The primary endpoint in this study is overall survival
- Survival of HCT subjects vs. conventional therapy subjects, immune reconstitution, engraftment, andclinical outcomes such as infection, autoimmune disease and inflammatory complications, GvHD, growth, and quality of life.
|
120 |
All |
2 Years and older (Child, Adult, Senior) |
NCT02116764 |
140091
14-I-0091 |
|
April 15, 2014 |
July 1, 2018 |
July 1, 2019 |
April 17, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 34 |
NCT02231879 |
Recruiting |
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome |
- Myelokathexis
- WHIMS
- Neutropenia
- Warts
|
- Drug: Plerixafor
- Drug: G-CSF
|
Interventional |
Phase 3 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The primary endpoint is infection severity, which is measured as a composite of multiple weighted parameters according to rules defined in Appendix D of the protocol.
- Component measures of infections; incidence and duration of infections, fevers, antibiotic treatments, and hospitalization.
- Control of warts as defined by at least a 50% reduction in numbers, areas or size of existing warts and number of new warts.
- Blood count and immunological parameters.
|
30 |
All |
10 Years to 75 Years (Child, Adult, Senior) |
NCT02231879 |
140185
14-I-0185 |
|
September 3, 2014 |
September 30, 2020 |
March 31, 2021 |
September 4, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 35 |
NCT02147405 |
Recruiting |
PET Imaging and Lymph Node Assessment of IRIS in People With AIDS |
- Immune Reconstitution Inflammatory Syndrome
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlate LN inflammation (by FDG-PET) and degree of fibrosis as assessed by immunohistochemistry (IHC) with development of IRIS and degree of immune reconstitution after 1 year of ART.
- Pathogenesis studies to evaluate role of myeloid cells in periphery and LN in IRIS.
- FDG-PET measurements and correlations with viremia, biomarkers, OI, immune recovery of B cells and Tfh cells with ART.
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02147405 |
140124
14-I-0124 |
|
May 22, 2014 |
April 1, 2019 |
April 1, 2020 |
May 26, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 36 |
NCT02081638 |
Recruiting |
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study |
|
- Drug: Aspirin 81 mg daily
- Drug: Atorvastatin 40 mg daily
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- The primary end point will be change of sCD14 from Month 3 to Month 12 in the two groups combined (EC and ART <50).
- Changes in soluble biomarkers (sCD14, IL-6, D-dimer, hsCRP, sCD163, sTF as well as other relevant markers of inflammation and coagulation) in EC and ART <50 groups treated with ASA or ATV, independently within each group and arm and with grou...
- Changes in T cell activation (measured by HLA-DR/CD38 co- expression), monocyte immune activation (measured by activated monocyte subsets expressing either CD14++CD16+ and CD14varCD16+ and markers of activation, CCR5 and TF, and migration, CCR2 ...
- Changes in MR imaging of carotids after 9 months of statin or ASA in each group and both groups combined.
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02081638 |
140039
14-I-0039 |
|
March 5, 2014 |
November 30, 2019 |
November 30, 2019 |
March 7, 2014 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Hennipen County Medical Center
Minneapolis, Minnesota, United States
|
| 37 |
NCT01976715 |
Recruiting |
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy |
- Acquired Immune Deficiency Syndrome Virus
- Acquired Immunodeficiency Syndrome Virus
- AIDS Virus
- (and 2 more...)
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The log viral load change over time during the study enrollment period
- Log viral load change during the inpatient directly observed therapy period
|
150 |
All |
14 Years to 100 Years (Child, Adult, Senior) |
NCT01976715 |
140009
14-I-0009 |
|
October 30, 2013 |
August 1, 2022 |
September 1, 2023 |
November 6, 2013 |
April 17, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 38 |
NCT02015013 |
Recruiting |
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models |
- T-Lymphocytopenia, Idiopathic CD4-Positive
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
- to assess peripheral CD4 T cell and CD34 plus hematopoietic progenitor cell numbers and functions in ICL patients compared to controls following G-CSF and plerixafor administration.
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT02015013 |
140020
14-I-0020 |
|
December 13, 2013 |
October 31, 2018 |
January 1, 2019 |
December 19, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 39 |
NCT01851460 |
Recruiting |
Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease |
- Chronic Granulomatous Disease (CGD)
|
- Device: Cool-tip RF Ablation System
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to determine the safety ofradiofrequency ablation (RFA) in the treatment of liver abscesses insubjects with chronic granulomatous disease (CGD).
- To determine if RFA is a reasonable treatment option for patients with liver abscesses who are not suitable candidates for completely curative hepatic surgery
- To compare the recovery outcomes of patients undergoing RFA versus historical controls for patients undergoing surgery for treatment of liver abscesses
|
30 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01851460 |
130117
13-I-0117 |
|
May 8, 2013 |
January 1, 2020 |
January 1, 2021 |
May 10, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 40 |
NCT01842386 |
Recruiting |
Rituximab for Anti-cytokine Autoantibody-Associated Diseases |
- Anticytokine Autoantibody-Associated Diseases
- Disseminated Non-Tuberculous Mycobacteria
- Chronic Mucocutaneous Candidiasis
- Pulmonary Alveolar Proteinosis (PAP)
|
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The evaluation of adverse events to determine the safety and tolerability of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment.
- Evaluation of changes in autoantibody titers in response to rituximab treatment.
- Assessment of the effects of rituximab on autoantibody-mediatedclinical disease.
- The measurement of both qualitative and quantitative differences in antibody composition and immune function after treatment with rituximab.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01842386 |
130082
13-I-0082 |
|
April 25, 2013 |
January 1, 2025 |
January 1, 2025 |
April 29, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 41 |
NCT01593709 |
Recruiting |
Volunteer Screening for Vaccine and Antivirals Clinical Trials |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- To screen subjects for their eligibility to participate in clinical trials of investigational or licensed vaccines, antiviral products, or live virus challenge studies being evaluated for research purposes.
|
1000 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01593709 |
120121
12-I-0121 |
|
May 15, 2012 |
|
|
May 8, 2012 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 42 |
NCT01524536 |
Recruiting |
Steroid Treatment for Hypereosinophilic Syndrome |
|
|
Interventional |
Phase 4 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To develop a model to determine whether a single dose steroid challenge can be used to predict GC responsiveness in subjects with HES
- To define a group of GC non-responders and/or suboptimal responders for further study of the mechanisms and biologic correlates of GC resistance in HES
- To delineate some of the mechanisms of decreased GC responsiveness in GC-resistant subjects and to assess in-vitro correlates of therapeutic responsiveness in HES
|
100 |
All |
7 Years to 100 Years (Child, Adult, Senior) |
NCT01524536 |
120026
12-I-0026 |
|
November 23, 2011 |
December 31, 2018 |
December 31, 2019 |
February 2, 2012 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 43 |
NCT01306019 |
Recruiting |
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) |
- X-linked Severe Combined Immunodeficiency
- XSCID
- SCID-X1
- Gamma C-Deficient SCID
|
- Other: Gene-modified CD34+ Hematopoietic stem cells
- Drug: Busulfan
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective is to assess the efficacy of immune reconstitution in XSCID patients transplanted with autologous CD34 plus cells that have been transduced with a self-inactivating lentiviral vector expressing a Gamma C gene.
- To determine the incidence of serious side effects due to lentiviral gene transfer.
- To determine the integration site distribution of the lentiviral vector in reconstituted peripheral blood cells.
|
20 |
All |
2 Years to 40 Years (Child, Adult) |
NCT01306019 |
110007
11-I-0007 |
|
February 26, 2011 |
December 31, 2022 |
December 31, 2025 |
March 1, 2011 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 44 |
NCT01322581 |
Recruiting |
A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identify genome-wide expression profiles induced by Pf infection thatare associated with malaria immunity.
|
1200 |
All |
3 Months to 40 Years (Child, Adult) |
NCT01322581 |
999911126
11-I-N126 |
|
March 23, 2011 |
|
|
March 24, 2011 |
April 13, 2018 |
|
- University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology
Bamako, Mali
|
| 45 |
NCT01164241 |
Recruiting |
Natural History of Diseases Associated With Allergic Inflammation: Atopic Dermatitis and Genetic and Congenital Diseases Associated With Atopic Pathways |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Study the natural history of diseases of allergic inflammation, focusing on subjects with moderate to severe atopic dermatitis or with suspected genetic or congenital disorders associated with allergic inflammation
|
1650 |
All |
2 Years to 80 Years (Child, Adult, Senior) |
NCT01164241 |
100148
10-I-0148 |
|
June 22, 2010 |
|
|
July 16, 2010 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 46 |
NCT01123499 |
Recruiting |
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
- To collect cells from normal volunteers using both G-CSF and plerixafor so as to be able to use these in various research applications.
- To characterize the frafts obrained from normal donors using G-CSF and plerixafor and to compare these grafts to historical grafts collected using g-CSF alone.
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT01123499 |
100095
10-I-0095 |
|
April 28, 2010 |
|
|
May 14, 2010 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 47 |
NCT00936325 |
Recruiting |
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome |
- Systemic Capillary Leak Syndrome
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
210 |
All |
16 Years to 80 Years (Child, Adult, Senior) |
NCT00936325 |
090184
09-I-0184 |
|
July 8, 2009 |
|
|
July 10, 2009 |
April 20, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 48 |
NCT00967785 |
Recruiting |
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS |
- WHIMS
- Neutrophil Disorder
- Myelokathexis
- Hypogammaglobulinemia
|
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine whether or not Mozobil (TM) is safe in study population.
- Whether or not treatment results in increased ANC.
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00967785 |
090200
09-I-0200 |
|
August 4, 2009 |
June 1, 2019 |
December 31, 2019 |
August 28, 2009 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 49 |
NCT00719719 |
Recruiting |
Cause of Unexplained Anaphylaxis |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Clinical samples obtained from the bone marrow biopsy and whole blood will be used to determine genetic and signaling abnormalities in mast cells and will be correlated with clinical features of idiopathic anaphylaxis.
- Clinical samples obtained from the bone marrow biopsy and whole blood will be used investigate the presence or absence of a monoclonal mast cell disorder.
|
200 |
All |
13 Years to 70 Years (Child, Adult, Senior) |
NCT00719719 |
080184
08-I-0184 |
|
July 18, 2008 |
|
|
July 22, 2008 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 50 |
NCT00852943 |
Recruiting |
Screening Protocol for Genetic Diseases of Allergic Inflammation |
- Piebaldism
- Idiopathic Anaphylaxis
- Allergy
- (and 2 more...)
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
- Designed to screen subjects with suspected or identified genetic diseases of allergic inflammation or of mast cell homeostasis and activation. Blood specimens will be obtained for research studies related to understanding the genetic and biochem...
|
1000 |
All |
1 Year to 80 Years (Child, Adult, Senior) |
NCT00852943 |
090086
09-I-0086 |
|
February 25, 2009 |
|
|
February 27, 2009 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
Create an RSS feed from your search for:
Download the search results for: